191348-04-6

Basic information

• Product Name: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate;(3S)-3-Formyl-1-pyrrolidinecarboxylic acid tert-butyl ester;S-1-Boc-3-pyrrolidinecarbaldehyde;(S)-3-forMyl-1-Boc-pyrrolidine
• CAS NO: 191348-04-6
• Molecular Formula: C10H17NO3
• Molecular Weight: 199.248
• Mol File: 191348-04-6.mol
• Article Data: 40

Chemical Properties

• Boiling Point: 276.3±33.0 °C(Predicted)
• Appearance: /
• Density: 1.148
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.44±0.40(Predicted)
• CAS DataBase Reference: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate(191348-04-6)
• EPA Substance Registry System: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate(191348-04-6)

Safety Data

• Hazardous Substances Data: 191348-04-6(Hazardous Substances Data)

Usage

Uses

(S)-tert-Butyl 3-formylpyrrolidine-1-carboxylate is a useful research chemical.

Upstream product

• 199174-24-8 tert-butyl (3S)-3-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 201230-82-2 carbon monoxide 
• 73286-71-2 N-(tert-butoxycarbonyl)-2,3-dihydropyrrole 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 59378-87-9 pyrrolidine-3-carboxylic acid 
• 98548-90-4 methyl pyrrolidine-3-carboxylate 
• 122684-33-7 methyl 1-tert-butoxycarbonyl-3-pyrrolidinecarboxylate 
• 72925-16-7 1-boc-pyrrolidine-3-carboxylic acid 
• 569667-93-2 tert-butyl 3-(methoxy(methyl)carbamoyl)pyrrolidine-1-carboxylate 
• 35309-35-4 5-oxopyrrolidine-3-carboxylic acid methyl ester 
• 617-52-7 Dimethyl itakonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 85310-69-6 pyrrolidin-3-ylmethanol 
• 114214-69-6 tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate 

Downstream Products

• 72925-16-7 1-boc-pyrrolidine-3-carboxylic acid 
• 1588423-79-3 C₁₆H₂₂ClN₃O₃ 
• 1588423-78-2 C₁₆H₂₄ClN₃O₃ 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

C11-CYCLIC SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF

Provided are 13-membered macrolides for the treatment of infectious diseases. The 13- membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions comprising the 13-